Send to

Choose Destination
J Bone Metab. 2017 May;24(2):91-96. doi: 10.11005/jbm.2017.24.2.91. Epub 2017 May 31.

Fracture Preventing Effects of Maxmarvil® Tablets (Alendronate 5 mg + Calcitriol 0.5 µg) in Patients with Osteoporosis.

Author information

Department of Orthopaedic Surgery, Gyeongsang National University Hospital, Jinju, Korea.
Department of Orthopaedic Surgery, Chung-Ang University College of Medicine, Seoul, Korea.
Department of Orthopaedic Surgery, Ajou University College of Medicine, Suwon, Korea.
Department of Orthopaedic Surgery, Yonsei University College of Medicine, Seoul, Korea.
Department of Orthopaedic Surgery, Konyang University Hospital, Daejeon, Korea.
Department of Orthopaedic Surgery, National Health Insurance Corporation Ilsan Hospital, Goyang, Korea.
Department of Orthopaedic Surgery, Chungbuk National University College of Medicine, Cheongju, Korea.



The purpose of this prospective, open-label, observational study was to assess the fracture preventing effect of Maxmarvil® tablets (alendronate 5 mg + calcitriol 0.5 µg) in patients with osteoporosis and to evaluate the change in bone mineral density (BMD) at the minimum 1-year follow-up.


In this multicenter observational study, 691 patients with osteoporosis (aged 50 years or older) were treated with alendronate 5 mg + calcitriol 0.5 µg/day during their normal course of care. Patients were assessed at baseline and at 6 and 12 months. Baseline characteristics (including age, gender, concomitant disease, and baseline fractures) were evaluated.


From among the 848 participants, 149 individuals were lost to follow-up at the time of the study and 8 people had died. The 691 participants (54 men and 637 women) finished the follow-up study and completed the questionnaire. The mean age of the participants was 71.5 years (range, 50-92 years; mean age, 72.3 years for men and 71.4 years for women). Osteoporotic fracture occurred in 19 patients (2.7%). BMD of the lumbar spine and hip was improved by 5% and 1.5% at the latest follow-up. At the latest follow-up, 24 patients (3.5%) complained of drug-related complications such as dyspepsia, constipation, and nausea.


This prospective observational study demonstrated that alendronate 5 mg + calcitriol 0.5 µg/day had a preventive effect on osteoporotic fracture and it increased the BMD of the lumbar spine by 5% at the latest follow-up.


Alendronate; Bone density; Calcitriol; Osteoporosis; Osteoporotic fractures

Supplemental Content

Full text links

Icon for The Korean Society for Bone and Mineral Research Icon for PubMed Central
Loading ...
Support Center